Что такое операция SADI

[V. Fedenko]

Меня очень интересует - где можно посмотреть?

Здесь:

Зарегистрируйтесть для просмотра ссылок

[Elena73]

Вадим Викторович,а есть ли статистика,если реконструировать Слив в Sadi,можно ли еще похудеть-моему Сливу 3,5 года,но я не дохудела.
Хотелось бы еще сбросить немного.

[deder]

Моему сливу чуть меньше 3 лет, вес опять пошел в гору Хочу SADI!! Но, нигде не нахожу цены на реконструкцию из слива.

[Рюрикович]

За видео спасибо. Но ещё хотелось бы посмотреть статистику с детальной раскладкой. Вы обещали выслать ссылки на полнотекстовые статьи.

[monika]

22 марта мне делают SADI

[Solek]

Первопроходец!!! Удачи во всем и потом нам все все всешеньки расскажите пожалуйста!!!)

[monika]

Спасибо Solek
Обязательно все расскажу 😊

[Saga]

Моника, в какой клинике делаешь? никогда не встречала инфы об этой оп у нас.

[V. Fedenko]

За видео спасибо. Но ещё хотелось бы посмотреть статистику с детальной раскладкой. Вы обещали выслать ссылки на полнотекстовые статьи.

Surg Obes Relat Dis. 2015 Sep-Oct;11(5):1092-8. doi: 10.1016/j.soard.2015.01.024. Epub 2015 Feb 7.
Single-anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S) for obese diabetic patients.
Sánchez-Pernaute A1, Rubio MÁ2, Cabrerizo L2, Ramos-Levi A3, Pérez-Aguirre E4, Torres A4.
Author information
Abstract
BACKGROUND:
Bariatric operations achieve a high remission rate of type 2 diabetes in patients with morbid obesity. Malabsorptive operations usually are followed by a higher rate of metabolic improvement, though complications and secondary effects of these operations are usually higher.
OBJECTIVES:
Analyze the results of a simplified duodenal switch, the single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) on patients with obesity and type 2 diabetes mellitus (T2 DM).
SETTING:
University Hospital, Madrid, Spain.
METHODS:
Ninety-seven T2 DM patients with a mean body mass index (BMI) of 44.3 kg/m(2) were included. Mean preoperative glycated hemoglobin was 7.6%, and mean duration of the disease was 8.5 years. Forty patients were under insulin treatment. SADI-S was completed with a sleeve gastrectomy performed over a 54 French bougie and a 200 cm common limb in 28 cases and 250 cm in 69.
RESULTS:
Follow up was possible for 86 patients (95.5%) in the first postoperative year, 74 (92.5%) in the second, 66 (91.6%) in the third, 46 (86.7%) in the fourth and 25 out of 32 (78%) in the fifht postoperative year. Mean glycemia and glycated hemoglobin decreased immediately. Control of the disease, with HbA1c below 6%, was obtained in 70 to 84% in the long term, depending on the initial antidiabetic therapy. Most patients abandoned antidiabetic therapy after the operation. Absolute remission rate was higher for patients under oral therapy than for those under initial insulin therapy, 92.5% versus 47% in the first postoperative year, 96.4% versus 56% in the third and 75% versus 38.4% in the fifth. A short diabetes history and no need for insulin were related to a higher remission rate. Three patients had to be reoperated for recurrent hypoproteinemia.
CONCLUSION:
SADI-S is an effective therapeutic option for obese patients with diabetes mellitus.

[V. Fedenko]

Surg Obes Relat Dis. 2015 Mar-Apr;11(2):351-5. doi: 10.1016/j.soard.2014.06.016. Epub 2014 Jul 10.
Single-anastomosis duodenoileal bypass as a second step after sleeve gastrectomy.
Sánchez-Pernaute A1, Rubio MÁ2, Conde M3, Arrue E3, Pérez-Aguirre E3, Torres A3.
Author information
Abstract
BACKGROUND:
After sleeve gastrectomy, many surgical options are available in patients with insufficient weight loss. Duodenal switch is typically considered the operation that results in higher weight loss, although it is, perhaps unjustly, considered technically difficult and may be accompanied by severe side effects. Single-anastomosis duodenoileal bypass with sleeve gastrectomy is a simplification of the duodenal switch that may behave as a standard biliopancreatic diversion but is easier and quicker to perform. Given its effectiveness as a primary surgery we hypothesized that it would be successful as a second-step operation. The objective of this study was to analyze the weight loss and co-morbidities resolution after a single-anastomosis duodenoileal bypass (SADI) performed as a second step after sleeve gastrectomy.
METHODS:
Sixteen patients with an initial body mass index of 56.4 kg/m(2) and a mean excess weight loss of 39.5% after a sleeve gastrectomy were submitted to a single-anastomosis duodenoileal bypass with a 250-cm common channel.
RESULTS:
There were no postoperative complications. The mean excess weight loss was 72% 2 years after the second-step surgery. The complete remission rate was 88% for diabetes, 60% for hypertension, and 40% for dyslipidemia. The mean number of daily bowel movements was 2.1. One patient suffered an isolated episode of clinical hypoalbuminemia.
CONCLUSION:
SADI is a safe operation that offers a satisfactory weight loss for patients subjected to a previous sleeve gastrectomy. The side effects are well tolerated, and complications are minimal.